Rumi 1996.

Methods	Allocation concealment: unclear. Blinding: yes. Intention to treat: no. Methodological score: 16.
Participants	NAIVE PATIENTS WITH CHRONIC HEPATITIS C Arms: 116/118 Excluded: 13/11 Mean age : 49/48 % males: 69/67 % transfusion: 16/19 % drug abuse: 7/8 % cirrhosis: 26/31 Genotypes: G1 (63/53%), G2,3 (33/43%), other (4/3%) Disease duration: NDA
Interventions	Experimental 1: Alfa‐n‐1 IFN 6MU TIW until ALT normal then 3 MU TIW x total of 12 mo Experimental 2: Alfa‐2a IFN 6MaU TIW until ALT normal at least 4 wk then 3 MU TIW x total of 12 mo In both groups, if ALT broke through, the 6MU dose was reintroduced; IFN was stopped if ALT not normal within 24 wk. Follow‐up: 12 mo
Outcomes	‐ biochemical ETR and SR ‐ virologic ETR and SR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear